Cullen/Frost Bankers, Inc. Genmab A/S Transaction History
Cullen/Frost Bankers, Inc.
- $7.21 Billion
- Q4 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Genmab A/S stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 170 shares of GMAB stock, worth $3,289. This represents 0.0% of its overall portfolio holdings.
Number of Shares
170
Previous 146
16.44%
Holding current value
$3,289
Previous $3,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding GMAB
# of Institutions
233Shares Held
52.3MCall Options Held
10.2KPut Options Held
25.5K-
Alliancebernstein L.P. New York, NY15.1MShares$293 Million0.13% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$98.3 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA4.42MShares$85.6 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ3.07MShares$59.3 Million0.44% of portfolio
-
Wellington Management Group LLP Boston, MA2.31MShares$44.6 Million0.01% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $12.7B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...